Health ❯ Healthcare

Adverse Effects

Treatment-Emergent Adverse Effects Drug Safety Medication Side Effects Treatment-Related Adverse Effects Cytokine Release Syndrome Safety Profiles Treatment-Related Adverse Events Vaccine Safety Vaccine Side Effects Gastrointestinal Issues

FDA Panel Backs Capivasertib With Abiraterone in PTEN-Deficient Metastatic Prostate Cancer

The advisory vote guides a pending FDA decision on a targeted option for PTEN-deficient prostate cancer.

Cadonilimab Plus Chemo Delivers Strong Phase 2 Signal in Frontline Endometrial Cancer

Mexico Renews Warning as Counterfeit GLP-1 Weight-Loss Drugs Spread Worldwide

3.1 Million Bottles of Store-Brand Eye Drops Recalled for Sterility Concerns

FDA Approves Nivolumab Plus AVD as First-Line Therapy for Advanced Hodgkin Lymphoma

NEJM Study Pinpoints Adenoviral Protein Behind Rare Clots in AstraZeneca and J&J COVID Vaccines

NEJM Study Identifies Viral Protein and Antibody Mutation Behind Rare Vaccine‑Linked Clots

UK Regulator Adds Severe Pancreatitis Warning to Ozempic, Wegovy and Mounjaro

Moderna–Merck Personalized Melanoma Vaccine Sustains 5-Year Benefit, Cutting Recurrence Risk by 49%

Tucatinib Added to First-Line HER2 Maintenance Prolongs Progression-Free Survival in Phase 3 Trial

Sacituzumab Govitecan Gains First-Line Ground in TNBC, Falls Short in Early HR+/HER2− Use

Roche’s Giredestrant Cuts Early Breast Cancer Recurrence 30% in Phase III Trial

Teclistamab–Daratumumab Delivers Major Survival Gains in Relapsed Myeloma, Phase 3 Data Show

Structure Therapeutics' Oral GLP-1 Posts Up to 15% Placebo-Adjusted Weight Loss as Company Prepares Phase 3

KOMET-007 Shows 600 mg Ziftomenib Plus Venetoclax/Azacitidine Achieves Deep Remissions in NPM1‑Mutated AML

Early Cilta-Cel Use Linked to Better Outcomes in Relapsed/Refractory Myeloma, ASH 2025 Data Show

FDA Approves Breyanzi for Marginal Zone Lymphoma After Two or More Therapies

Pliant’s PLN-101095 With Keytruda Shows Early Responses in PD-1–Refractory Solid Tumors

FDA Approves Durvalumab Added to Perioperative FLOT for Resectable Gastric and GEJ Cancer

FDA Approves Perioperative Keytruda–Padcev for Cisplatin‑Ineligible Muscle‑Invasive Bladder Cancer